What is Lifebit?
Headquartered in London, Lifebit provides a sophisticated ecosystem centered on its CloudOS platform, which facilitates secure, integrated, and FAIR (Findable, Accessible, Interoperable, Reusable) omics and biomedical analysis. The company distinguishes itself by moving away from traditional data silos, instead enabling researchers to analyze sensitive information within their own secure environments. Complementing this infrastructure is the Lifebit AI-Engine, a proprietary tool that utilizes deep learning to interpret complex biological data, effectively assisting in target validation and drug repurposing. As the industry shifts toward data-driven medicine, Lifebit serves as a foundational layer for organizations aiming to streamline research workflows while maintaining rigorous security standards.
How much funding has Lifebit raised?
Lifebit has raised a total of $70.5M across 3 funding rounds:
Angel/Seed
$3M
Series A
$7.5M
Series B
$60M
Angel/Seed (2018): $3M, investors not publicly disclosed
Series A (2020): $7.5M led by Idinvest Partners, Beacon Capital Partners , LLC, Pentech Ventures LLP, and Connect Ventures
Series B (2021): $60M supported by Beacon Capital Partners, Eurazeo, Tiger Global Management, and Pentech Ventures
Key Investors in Lifebit
Tiger Global Management
A prominent investment firm that deploys capital across both public and private markets, known for supporting high-growth technology companies.
Eurazeo
A leading global investment company based in Paris that provides long-term support and sector expertise to companies undergoing transformational growth.
Pentech Ventures LLP
A venture capital firm focused on early-stage technology investments, providing strategic guidance to innovative startups in the European ecosystem.
What's next for Lifebit?
With the infusion of capital from its latest financing round, Lifebit is well-positioned to scale its operations and deepen its AI-driven research capabilities. The company is expected to focus on expanding its footprint within the global pharmaceutical market, where the demand for scalable, secure, and intelligent data analysis is at an all-time high. By continuing to refine its federated analysis models, Lifebit aims to reduce the time-to-market for critical therapeutic discoveries. Future strategic initiatives will likely involve enhancing the interoperability of its platform across diverse international research institutions, thereby solidifying its status as an essential utility for the next generation of precision medicine and biomedical innovation.
See full Lifebit company page
